Assessing Providers' knowledge about and barriers to lung cancer screening.
Jeffrey J Quezada, Axs R Avenido, Stephanie Jia...
https://pubmed.ncbi.nlm.nih.gov/39577140/Actively Recruiting
Led by University of California, Irvine · Updated on 2026-09-21
80
Participants Needed
57
Research Sites
17 weeks
Total Duration
Lung cancer is the leading cause of cancer-related death in the United States, and annual lung cancer screening with low-dose computed tomography LDCT has been shown to reduce mortality. However, many people who are eligible for screening based on U.S. Preventive Services Task Force guidelines do not undergo it. This study evaluates new strategies to improve lung cancer screening uptake among adults aged 50 to 80 with a significant smoking history. Participants will be randomly assigned to either enhanced usual care, which includes an educational brochure, or an intervention called Empower LCSCall. The Empower LCS intervention features patient education, provider notifications, patient reminders, and information about financial and community resources. Those who do not complete screening after the initial intervention may receive additional telephone navigation through the Call program to address barriers and assist with scheduling. Participants complete baseline and follow-up surveys at 4 and 8 months. Researchers will review electronic health records to assess discussions, orders, and completion of lung cancer screening. Some participants will also be invited to a one-time interview about their experiences. The study aims to assess the feasibility, acceptability, and preliminary effectiveness of the intervention to inform future efforts to improve equitable access to lung cancer screening.
CONDITIONS
Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+)
G
Gelareh Sadigh, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Irvine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Empower LCS/Call+ (multicomponent behavioral support) | Enhanced Usual Care (education only) | Current Guideline Standard: Annual LDCT |
|---|---|---|---|
| What it is | A behavioral intervention combining a decision aid, provider notification, reminders, tailored support materials and telephone navigation to encourage lung cancer screening | Provision of educational material only, outlining benefits and risks of lung cancer screening | Annual low‑dose CT screening is recommended by USPSTF for eligible adults aged 50‑80 with a smoking history of ≥20 pack‑years |
| Role in trial | Investigational behavioral strategy tested to increase screening uptake | Active comparator providing educational information about screening | Represents current guideline‑based screening approach outside the trial |
| Primary use | To support eligible adults in completing lung cancer screening | To provide basic educational information and encourage screening | To detect lung cancer early in high‑risk adults following national screening guidelines |
| How it’s delivered | Delivered through decision aid, provider alerts, text reminders, tailored materials, and lay‑navigator phone support | One‑page printed educational material provided to participants | Screening via annual low‑dose computed tomography scan |
| Evidence status | Efficacy being evaluated in this randomized trial; results pending | Efficacy in supporting screening relative to experimental strategy being assessed | Annual LDCT screening reduces lung cancer mortality in high‑risk adults based on meta‑analyses of trials and USPSTF recommendation |
| Important risks | No direct safety risks; addresses behavioral engagement only | No known safety risks from educational materials | LDCT screening carries risks of radiation, false positives, overdiagnosis, and downstream testing |
| Important limitations | Effectiveness unknown until trial completion; requires multi‑step engagement which may limit real‑world uptake | Education alone may insufficiently address barriers to completing screening | Requires access to CT facilities, follow‑up care, and may have limited reach in underserved populations |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual)
Duration - 8 months
Participants are randomly assigned to receive either enhanced usual care with educational materials or the Empower LCS/Call+ intervention, which includes education, reminders, and telephone navigation for those who do not complete screening initially.
Baseline survey and follow-up surveys at 4 and 8 months
Duration - Up to 8 months after randomization
Researchers review electronic health records and participant surveys to assess lung cancer screening discussions, orders, and completion. Some participants may be invited for a one-time interview about their study experience.
Surveys at 4 and 8 months, and one-time interview for some participants
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jeffrey J Quezada, Axs R Avenido, Stephanie Jia...
https://pubmed.ncbi.nlm.nih.gov/39577140/Jinho Jung, Eisa Razzak, Axs Roc Avenido...
https://pubmed.ncbi.nlm.nih.gov/40044305/Alireza Shojazadeh, Raymond Kao, Thao Pham...
https://pubmed.ncbi.nlm.nih.gov/41241060/A M O'Connor
https://pubmed.ncbi.nlm.nih.gov/7898294/National Lung Screening Trial Research Team, Denise R Aberle, Amanda M Adams...
https://pubmed.ncbi.nlm.nih.gov/21714641/Lisa Carter-Harris, James E Slaven, Patrick Monohan...
https://pubmed.ncbi.nlm.nih.gov/27244666/University of California, Irvine
Lead Sponsor